Aida Malek Mahdavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aida Malek Mahdavi has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Alireza Khabbazi
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
17 shared publications- Alireza Khabbazi
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
17 shared publications Zeinab Javadivala
Department of Health Education and Promotion, Tabriz University of Medical Sciences, Tabriz, Iran
12 shared publications- Sousan Kolahi
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
7 shared publications Kamal Esalatmanesh
Internal Medicine Group, Kashan University of Medical Sciences, Kashan, Iran
6 shared publicationsMehrzad Hajialilo
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Taurine supplementation and systemic lupus erythematosus in preclinical studies: a systematic review of clinical outcomes and underlying mechanisms
Taurine (Tau) is a sulfur-containing amino acid that has therapeutic roles in several diseases, including inflammatory conditions. The involvement of Tau in modulating systemic lupus erythematosus (SLE) autoimmunity has been indicated in preclinical models, but reports are contradictory. This systematic review aimed to summarize current research regarding the potential role of Tau in SLE, to notice knowledge gaps, and to offer suggestions for the way ahead. The literature search was carried out using PubMed, Scopus, Web of Science, and Google Scholar databases until October 2025. Search alert services were also applied to notice related papers published after the primary search. All studies investigating the effects of Tau in SLE that met the inclusion criteria were eligible. Out of 77 articles initially found, only six preclinical studies (animal and in-vitro) were eligible, and no qualified clinical study was identified. Five studies indicated that Tau was helpful in improving clinical parameters, decreasing T helper 1 (Th1) and Th17 cells and inflammatory mediators (e.g., tumor necrosis factor-α, C-reactive protein, and inducible nitric oxide synthase), removing reactive oxygen species and decreasing oxidative markers like malondialdehyde, increasing regulatory T (Treg) and Th2 cells and anti-inflammatory interleukin-4 and interleukin-10 cytokines, increasing antioxidant enzymes superoxide dismutase and glutathione peroxidase, and inhibiting both FAS- and mitochondrial-dependent apoptotic signaling components. However, only one preclinical study reported that Tau aggravated SLE progression characterized by increased generation of type I interferons, enhanced autoantibodies and proteinuria, further lymphocyte activation, and critical nephritis. The current review provides evidence about the role of Tau in SLE and highlights the importance of further well-designed clinical trials to confirm these results, establish optimal dose and assess safety and long-term efficacy.
- 24 March 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Open AccessTaurine supplementation and systemic lupus erythematosus in preclinical studies: a systematic review of clinical outcomes and underlying mechanisms
Taurine (Tau) is a sulfur-containing amino acid that has therapeutic roles in several diseases, including inflammatory conditions. The involvement of Tau in modulating systemic lupus erythematosus (SLE) autoimmunity has been indicated in preclinical models, but reports are contradictory. This systematic review aimed to summarize current research regarding the potential role of Tau in SLE, to notice knowledge gaps, and to offer suggestions for the way ahead. The literature search was carried out using PubMed, Scopus, Web of Science, and Google Scholar databases until October 2025. Search alert services were also applied to notice related papers published after the primary search. All studies investigating the effects of Tau in SLE that met the inclusion criteria were eligible. Out of 77 articles initially found, only six preclinical studies (animal and in-vitro) were eligible, and no qualified clinical study was identified. Five studies indicated that Tau was helpful in improving clinical parameters, decreasing T helper 1 (Th1) and Th17 cells and inflammatory mediators (e.g., tumor necrosis factor-α, C-reactive protein, and inducible nitric oxide synthase), removing reactive oxygen species and decreasing oxidative markers like malondialdehyde, increasing regulatory T (Treg) and Th2 cells and anti-inflammatory interleukin-4 and interleukin-10 cytokines, increasing antioxidant enzymes superoxide dismutase and glutathione peroxidase, and inhibiting both FAS- and mitochondrial-dependent apoptotic signaling components. However, only one preclinical study reported that Tau aggravated SLE progression characterized by increased generation of type I interferons, enhanced autoantibodies and proteinuria, further lymphocyte activation, and critical nephritis. The current review provides evidence about the role of Tau in SLE and highlights the importance of further well-designed clinical trials to confirm these results, establish optimal dose and assess safety and long-term efficacy.
- 16 March 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (5) , 2505-2513
Association between body mass index and palindromic rheumatism risk and outcomes: a case–control study
Aim Palindromic rheumatism (PR) is a periodic rheumatic disease characterized by recurrent attacks of pain and swelling, affecting articular and periarticular structures. Despite the evidence supporting the association between overweight and obesity with autoimmune rheumatic diseases, the relation between body mass index (BMI) and PR remains underexplored. Therefore, this research aimed to evaluate the possible association between BMI and PR risk and outcomes. Methods This cross-sectional study utilized data from the CTDRC-PR Cohort. The PR group consisted of adults (age ≥ 18 years) diagnosed with PR according to the Guerne & Weisman criteria. Healthy controls (HCs) were selected from the general population enrolled in the Azar Cohort Study. Results Of the 229 patients followed in the CTDRC-PR cohort, 151 met the study inclusion criteria. Following 1:2 propensity score matching, the final analytical sample consisted of 147 PR patients and 294 matched HCs. No significant difference was observed in mean BMI between PR patients and HCs. In a multivariate logistic regression model adjusted for age, sex, marital status, and smoking status, BMI ≥ 25 kg/m2 was associated with an increased risk of PR. No significant differences were found in demographic profiles, clinical presentation, disease activity levels, or rates of remission between overweight/obese PR patients and those with lean/normal weight. Conclusion The lack of association between BMI and PR risk or outcomes may reflect the unique immunological positioning of PR, which differs from classical autoimmune pathways sensitive to adiposity. It also underscores the limitations of BMI as a surrogate for metabolically active adipose tissue. Key Points • No significant difference was observed in mean BMI between PR patients and HCs. • In a multivariate logistic regression model adjusted for age, sex, marital status, and smoking status, neither overweight nor obesity was associated with an increased risk of PR.
- 16 March 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (5) , 2505-2513
Association between body mass index and palindromic rheumatism risk and outcomes: a case–control study
Aim Palindromic rheumatism (PR) is a periodic rheumatic disease characterized by recurrent attacks of pain and swelling, affecting articular and periarticular structures. Despite the evidence supporting the association between overweight and obesity with autoimmune rheumatic diseases, the relation between body mass index (BMI) and PR remains underexplored. Therefore, this research aimed to evaluate the possible association between BMI and PR risk and outcomes. Methods This cross-sectional study utilized data from the CTDRC-PR Cohort. The PR group consisted of adults (age ≥ 18 years) diagnosed with PR according to the Guerne & Weisman criteria. Healthy controls (HCs) were selected from the general population enrolled in the Azar Cohort Study. Results Of the 229 patients followed in the CTDRC-PR cohort, 151 met the study inclusion criteria. Following 1:2 propensity score matching, the final analytical sample consisted of 147 PR patients and 294 matched HCs. No significant difference was observed in mean BMI between PR patients and HCs. In a multivariate logistic regression model adjusted for age, sex, marital status, and smoking status, BMI ≥ 25 kg/m2 was associated with an increased risk of PR. No significant differences were found in demographic profiles, clinical presentation, disease activity levels, or rates of remission between overweight/obese PR patients and those with lean/normal weight. Conclusion The lack of association between BMI and PR risk or outcomes may reflect the unique immunological positioning of PR, which differs from classical autoimmune pathways sensitive to adiposity. It also underscores the limitations of BMI as a surrogate for metabolically active adipose tissue. Key Points • No significant difference was observed in mean BMI between PR patients and HCs. • In a multivariate logistic regression model adjusted for age, sex, marital status, and smoking status, neither overweight nor obesity was associated with an increased risk of PR.
- Open Access
- 26 February 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (3)
Evaluating Potential Effects of Chamomile ( Matricaria chamomilla L .) in Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis
The present study aimed to systematically assess the effects of Chamomile consumption on some biochemical parameters and clinical symptoms in patients with polycystic ovary syndrome (PCOS). The search was performed across the databases PubMed, Web of Science, Scopus, and Google Scholar using relevant keywords, with no language or date restrictions, up to the 4th of December 2024. Given the limited number of studies, results from both human and animal research were considered. The risk of bias for included studies was evaluated. For clinical studies, meta‐analyses were conducted using Stata, and a random‐effects model was used to estimate effect sizes. Four animal and four human studies were qualified for this review. Almost all animal studies indicated that Chamomile improved clinical, hormonal, and oxidative stress parameters in PCOS. Furthermore, almost all human studies have shown that Chamomile supplementation improves the clinical features of PCOS. However, the pooled analysis of two eligible human studies showed that there was no statistically significant effect of Chamomile supplementation on serum lipid profile including LDL‐C (ES = 1.73, 95% CI (−6.49, 9.94), p = 0.680), TG (ES = −7.23, 95% CI (−29.34, 14.89), p = 0.522), and HDL‐C (ES = −0.07, 95% CI (−5.85, 5.70), p = 0.980). Moreover, the pooled analysis of three eligible human studies demonstrated no statistically significant effect of Chamomile on serum testosterone levels (ES = 5.05, 95% CI = (−1.38, 11.49), p = 0.124). Overall, animal studies have demonstrated the potential benefits of Chamomile consumption in the treatment of PCOS, possibly through anti‐androgenic, anti‐inflammatory, analgesic, and antioxidant effects. In contrast, human studies yielded heterogeneous findings, with improvements in clinical features but no significant impact on serum testosterone or lipid profile parameters. Therefore, further well‐designed clinical trials are needed to make more definitive decisions.
- 26 February 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (3)
Open AccessEvaluating Potential Effects of Chamomile ( Matricaria chamomilla L .) in Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis
The present study aimed to systematically assess the effects of Chamomile consumption on some biochemical parameters and clinical symptoms in patients with polycystic ovary syndrome (PCOS). The search was performed across the databases PubMed, Web of Science, Scopus, and Google Scholar using relevant keywords, with no language or date restrictions, up to the 4th of December 2024. Given the limited number of studies, results from both human and animal research were considered. The risk of bias for included studies was evaluated. For clinical studies, meta‐analyses were conducted using Stata, and a random‐effects model was used to estimate effect sizes. Four animal and four human studies were qualified for this review. Almost all animal studies indicated that Chamomile improved clinical, hormonal, and oxidative stress parameters in PCOS. Furthermore, almost all human studies have shown that Chamomile supplementation improves the clinical features of PCOS. However, the pooled analysis of two eligible human studies showed that there was no statistically significant effect of Chamomile supplementation on serum lipid profile including LDL‐C (ES = 1.73, 95% CI (−6.49, 9.94), p = 0.680), TG (ES = −7.23, 95% CI (−29.34, 14.89), p = 0.522), and HDL‐C (ES = −0.07, 95% CI (−5.85, 5.70), p = 0.980). Moreover, the pooled analysis of three eligible human studies demonstrated no statistically significant effect of Chamomile on serum testosterone levels (ES = 5.05, 95% CI = (−1.38, 11.49), p = 0.124). Overall, animal studies have demonstrated the potential benefits of Chamomile consumption in the treatment of PCOS, possibly through anti‐androgenic, anti‐inflammatory, analgesic, and antioxidant effects. In contrast, human studies yielded heterogeneous findings, with improvements in clinical features but no significant impact on serum testosterone or lipid profile parameters. Therefore, further well‐designed clinical trials are needed to make more definitive decisions.
- 25 February 2026
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 48 (2) , 224-233
Galantamine supplementation and rheumatoid arthritis: a systematic review of current research and molecular mechanisms
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with an estimated prevalence of 0.5-1.0%, based on most epidemiological research [1]. It is marked by the frequent rise in autoanti...
- 25 February 2026
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 48 (2) , 224-233
Galantamine supplementation and rheumatoid arthritis: a systematic review of current research and molecular mechanisms
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with an estimated prevalence of 0.5-1.0%, based on most epidemiological research [1]. It is marked by the frequent rise in autoanti...
- 10 January 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 31
Mechanistic insights into propolis in targeting adipokines including leptin, resistin, and adiponectin: A systematic review
Background Propolis is a bioactive bee product that may influence adipokines involved in metabolic and inflammatory disorders; however, findings on leptin, adiponectin, and resistin are inconsistent across models and human studies. Current study aimed to systematically synthesize preclinical and clinical evidence on the effects of propolis and propolis-derived compounds on leptin, adiponectin, and resistin, and to summarize proposed mechanistic pathways. Methods The study protocol was registered in PROSPERO (CRD42024593198). We searched PubMed, Web of Science, Scopus, and Google Scholar to find related articles published between 1900 and 2025. We screened reference lists, and used alert services after the primary search. We included in vitro, animal, and human studies that were published in English language and evaluated propolis/propolis-derived compounds versus a comparator and reporting leptin, adiponectin, and resistin outcomes. Risk of bias was assessed using the CRIS guideline (in vitro), SYRCLE tool (animal), and Cochrane risk-of-bias tool (clinical trials). Findings were synthesized narratively due to heterogeneity. Results Twenty-six studies were included (9 in vitro, 11 animals, 6 human). In vitro studies generally reported decreased leptin and resistin expression and increased adiponectin expression following propolis-derived phenolics; one study reported increased leptin mRNA with a Brazilian propolis extract. In animal studies, leptin decreased in 5/8 studies and adiponectin increased in 5/9 studies, while remaining studies reported no change or opposite directions. Human trials showed mixed results: leptin decreased in 1/2 trials and adiponectin increased in 2/5 trials, whereas other trials reported no significant change. Substantial heterogeneity in propolis type/origin, formulation, dose, duration, and participant health status limited comparability. Conclusions Preclinical evidence suggests that propolis and selected constituents can modulate adipokines (often lowering leptin/resistin and increasing adiponectin), but clinical evidence is limited and inconsistent. Well-designed, adequately powered trials using standardized propolis preparations are required to clarify efficacy and translational relevance.
- 10 January 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 31
Mechanistic insights into propolis in targeting adipokines including leptin, resistin, and adiponectin: A systematic review
Background Propolis is a bioactive bee product that may influence adipokines involved in metabolic and inflammatory disorders; however, findings on leptin, adiponectin, and resistin are inconsistent across models and human studies. Current study aimed to systematically synthesize preclinical and clinical evidence on the effects of propolis and propolis-derived compounds on leptin, adiponectin, and resistin, and to summarize proposed mechanistic pathways. Methods The study protocol was registered in PROSPERO (CRD42024593198). We searched PubMed, Web of Science, Scopus, and Google Scholar to find related articles published between 1900 and 2025. We screened reference lists, and used alert services after the primary search. We included in vitro, animal, and human studies that were published in English language and evaluated propolis/propolis-derived compounds versus a comparator and reporting leptin, adiponectin, and resistin outcomes. Risk of bias was assessed using the CRIS guideline (in vitro), SYRCLE tool (animal), and Cochrane risk-of-bias tool (clinical trials). Findings were synthesized narratively due to heterogeneity. Results Twenty-six studies were included (9 in vitro, 11 animals, 6 human). In vitro studies generally reported decreased leptin and resistin expression and increased adiponectin expression following propolis-derived phenolics; one study reported increased leptin mRNA with a Brazilian propolis extract. In animal studies, leptin decreased in 5/8 studies and adiponectin increased in 5/9 studies, while remaining studies reported no change or opposite directions. Human trials showed mixed results: leptin decreased in 1/2 trials and adiponectin increased in 2/5 trials, whereas other trials reported no significant change. Substantial heterogeneity in propolis type/origin, formulation, dose, duration, and participant health status limited comparability. Conclusions Preclinical evidence suggests that propolis and selected constituents can modulate adipokines (often lowering leptin/resistin and increasing adiponectin), but clinical evidence is limited and inconsistent. Well-designed, adequately powered trials using standardized propolis preparations are required to clarify efficacy and translational relevance.
- 3 January 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (4) , 103363
Long-term Outcomes of Psoriatic Arthritis in Daily Practice: Results from a Real World Cohort
- 3 January 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (4) , 103363
Long-term Outcomes of Psoriatic Arthritis in Daily Practice: Results from a Real World Cohort
- 26 November 2025
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (2) , 559-567
Cigarette smoking and risk of undifferentiated peripheral inflammatory arthritis: a propensity score matching analysis
The present study investigated the association between smoking and undifferentiated peripheral inflammatory arthritis (UPIA) compared with healthy controls. Data were derived from the Connective Tissue Diseases Research Center Undifferentiated Arthritis (CTDRC-UA) cohort, which includes patients older than 16 years with persistent inflammatory arthralgia or arthritis for more than two weeks who do not fulfill classification criteria for any established rheumatic disease. A current smoker was defined as an individual actively smoking at study entry, while past smokers were those who had quit; both groups were categorized as ever smokers. After propensity score matching, 413 UPIA patients were compared with 413 matched controls. The prevalence of ever smoking was similar between UPIA and controls (9.3% vs. 9.4%). Multivariate analysis adjusted for age, sex, marital status, body mass index, and educational level showed no significant association between smoking and UPIA risk (OR 0.81, 95% CI 0.43–1.54, p = 0.523). During a median follow-up of 39 months, patients exhibited three disease trajectories: self-limited disease, progression to another rheumatic disease, or persistent undifferentiated arthritis. Smoking status did not differ significantly across these outcome groups. These findings suggest that smoking is not a universal risk factor for UPIA and does not substantially influence disease outcomes, underscoring the heterogeneity of UPIA and its complex gene–environment interactions. Future prospective studies with detailed exposure assessment should address current limitations—particularly in defining and quantifying smoking exposure—before integrating these results into broader evidence syntheses.
- 26 November 2025
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (2) , 559-567
Cigarette smoking and risk of undifferentiated peripheral inflammatory arthritis: a propensity score matching analysis
The present study investigated the association between smoking and undifferentiated peripheral inflammatory arthritis (UPIA) compared with healthy controls. Data were derived from the Connective Tissue Diseases Research Center Undifferentiated Arthritis (CTDRC-UA) cohort, which includes patients older than 16 years with persistent inflammatory arthralgia or arthritis for more than two weeks who do not fulfill classification criteria for any established rheumatic disease. A current smoker was defined as an individual actively smoking at study entry, while past smokers were those who had quit; both groups were categorized as ever smokers. After propensity score matching, 413 UPIA patients were compared with 413 matched controls. The prevalence of ever smoking was similar between UPIA and controls (9.3% vs. 9.4%). Multivariate analysis adjusted for age, sex, marital status, body mass index, and educational level showed no significant association between smoking and UPIA risk (OR 0.81, 95% CI 0.43–1.54, p = 0.523). During a median follow-up of 39 months, patients exhibited three disease trajectories: self-limited disease, progression to another rheumatic disease, or persistent undifferentiated arthritis. Smoking status did not differ significantly across these outcome groups. These findings suggest that smoking is not a universal risk factor for UPIA and does not substantially influence disease outcomes, underscoring the heterogeneity of UPIA and its complex gene–environment interactions. Future prospective studies with detailed exposure assessment should address current limitations—particularly in defining and quantifying smoking exposure—before integrating these results into broader evidence syntheses.
- Open Access
- 23 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (11)
High Prevalence of Cold Intolerance in Rheumatoid Arthritis: A Case–Control Study
Cold intolerance is more common in rheumatoid arthritis patients than control. Cold intolerance tends to develop after rheumatoid arthritis onset and is associated with longer disease duration, with pain and swelling being dominant features. Cold intolerance leads to a reduced quality of life in rheumatoid arthritis patients.
- 23 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (11)
Open AccessHigh Prevalence of Cold Intolerance in Rheumatoid Arthritis: A Case–Control Study
Cold intolerance is more common in rheumatoid arthritis patients than control. Cold intolerance tends to develop after rheumatoid arthritis onset and is associated with longer disease duration, with pain and swelling being dominant features. Cold intolerance leads to a reduced quality of life in rheumatoid arthritis patients.
- 17 September 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Spirulina supplementation and rheumatoid arthritis: A systematic review of current research and molecular mechanisms
- 17 September 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Spirulina supplementation and rheumatoid arthritis: A systematic review of current research and molecular mechanisms
- Open Access
- 25 June 2025
- Published by DoNotEdit in Rheumatology Research
- Vol. 10 (3) , 152-166
The impact of smoking on the risk, clinical manifestations, and outcomes of collagen vascular diseases: A comprehensive review
Collagen vascular diseases (CVDs) are a group of autoimmune disorders in which the immune system attacks connective tissue throughout the body, leading to multi-organ involvement. Cigarette smoke contains high concentrations of various toxic elements that can affect the innate and adaptive immune systems, causing immune responses to self-antigens or immune system suppression, thus having a dual function on immune system. In this review we considered the available evidence on the association between smoking and the risk, clinical manifestations, and outcomes of CVDs and the effect of smoking cessation on these parameters. In conclusion despite clear evidence of an increased risk of a number of CVDs including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), there is strong evidence that smokers have a lower risk of primary Sjögren''s syndrome (pSS). Furthermore, current evidence does not support a role for smoking in the incidence of systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), palindromic rheumatism (PR) and adult onset still disease (AOSD). Despite this, smoking change the clinical picture and outcomes of RA, SLE, pSS, SSc, IIM, PR and AOSD.
- 25 June 2025
- Published by DoNotEdit in Rheumatology Research
- Vol. 10 (3) , 152-166
Open AccessThe impact of smoking on the risk, clinical manifestations, and outcomes of collagen vascular diseases: A comprehensive review
Collagen vascular diseases (CVDs) are a group of autoimmune disorders in which the immune system attacks connective tissue throughout the body, leading to multi-organ involvement. Cigarette smoke contains high concentrations of various toxic elements that can affect the innate and adaptive immune systems, causing immune responses to self-antigens or immune system suppression, thus having a dual function on immune system. In this review we considered the available evidence on the association between smoking and the risk, clinical manifestations, and outcomes of CVDs and the effect of smoking cessation on these parameters. In conclusion despite clear evidence of an increased risk of a number of CVDs including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), there is strong evidence that smokers have a lower risk of primary Sjögren''s syndrome (pSS). Furthermore, current evidence does not support a role for smoking in the incidence of systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), palindromic rheumatism (PR) and adult onset still disease (AOSD). Despite this, smoking change the clinical picture and outcomes of RA, SLE, pSS, SSc, IIM, PR and AOSD.